Johnson & Johnson logo
Johnson & Johnson JNJ
report update icon

Quarterly report 2026-Q2
added 07-23-2026

Johnson & Johnson Balance Sheet 2025-2006 | JNJ

Brief overview of Johnson & Johnson's assets and capital

The review uses the five latest available annual reports between 2021 and 2025.

The balance sheet expanded from $174.9 billion to $199.2 billion. Growth of +13.9% and CAGR of 3.3% look measured and sustainable.

Assets outpaced liabilities, +13.9% versus +5.4%. Dependence on external funding declined.

Equity represents 40.9% of assets versus 36.2% initially. The capital structure appears balanced.

Net debt to equity stands at 0.27x; the current burden does not look excessive.

The cash reserve occupies 9.9% of the balance sheet, previously 8%. It is one marker of short-term resilience.

By the end of the period, accumulated earnings were $169 billion; the change from the start was +48.4%.

What the balance sheet shows

Johnson & Johnson's financial position is more positive than negative: the funding mix is workable, although the cushion is not unlimited.

Annual Balance Sheet Johnson & Johnson

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006

Net Debt

21.7 B 8.3 B 5.49 B 17.6 B 18.6 B - 22.2 B 24.5 B 18 B 14.2 B - 15.1 B 13.5 B 15.3 B 12.3 B -7.55 B - -2.65 B - -

Long Term Debt

39.4 B 30.7 B 25.9 B 30 B 32.6 B - 26.5 B 27.7 B 22.4 B 12.9 B - 15.1 B 13.3 B 13 B 9.16 B 8.22 B - 8.12 B - -

Long Term Debt Current

2 B 1.75 B 1.47 B 2.13 B - - - - 1.5 B - - - - - - 34 M - - - -

Total Non Current Liabilities

- - - - - - 62.3 B 62 B 44.5 B 34.5 B - 36.3 B 33 B 33.8 B 23.3 B - - - - -

Total Current Liabilities

54.1 B 50.3 B 46.3 B 45.2 B 42.5 B - 36 B 31.2 B 30.5 B 27.7 B - 25.1 B 25.7 B 24.3 B 23.1 B 21.7 B - 20.9 B - -

Total Liabilities

118 B 109 B 98.8 B 108 B 112 B - 98.3 B 93.2 B 70.8 B 62.3 B - 61.4 B 58.6 B 56.6 B 46.3 B 44.1 B - 42.4 B - -

Deferred Revenue

- - - - - - 7.82 B 7.64 B 6.15 B 5.49 B - 3.57 B 3.61 B 2.56 B 2.22 B - - - - -

Retained Earnings

169 B 156 B 154 B 123 B 114 B - 111 B 106 B 111 B 104 B - 97.2 B 89.5 B 81.3 B 77.8 B 70.3 B - 63.4 B - -

Total Assets

199 B 180 B 168 B 182 B 175 B - 158 B 153 B 141 B 133 B - 131 B 133 B 114 B 103 B 94.7 B - 84.9 B - -

Cash and Cash Equivalents

19.7 B 24.1 B 21.9 B 14.5 B 14 B - 17.3 B 18.1 B 17.8 B 13.7 B - 14.5 B 20.9 B 14.9 B 19.4 B 15.8 B - 10.8 B 7.77 B 4.08 B

Book Value

81.5 B 71.5 B 68.8 B 74 B 63.3 B - 59.5 B 59.8 B 70.4 B 71.2 B - 69.8 B 74.1 B 57.1 B 56.6 B 50.6 B - 42.5 B - -

Total Shareholders Equity

81.5 B 71.5 B 68.8 B 74 B 63.3 B - 59.5 B 59.8 B 60.2 B 71.2 B - 69.8 B 74.1 B 64.8 B 56.6 B 50.6 B - 42.5 B 43.3 B 39.3 B

All numbers in USD currency

Quarterly Balance Sheet Johnson & Johnson

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q3 2010-Q2 2010-Q1 2009-Q3 2009-Q2

Long Term Debt

37.3 B 37.5 B 39.4 B 39.2 B 38.4 B 31.3 B 31.6 B 25.1 B 26.1 B 33.9 B 34.9 B 26.9 B 27.6 B - 28.9 B 32.6 B 30.1 B 30.3 B 30.3 B - 32.7 B 25.1 B 25.4 B 26.5 B 26.5 B 26.5 B 26.5 B 27.7 B 27.7 B 27.7 B 27.7 B 30.7 B 30.7 B 30.7 B 30.7 B 12.9 B 23.5 B 24.5 B 20.2 B - 14.1 B 14.1 B 14.9 B 15.1 B 15.1 B 15.1 B 15.1 B 13.3 B 13.3 B 13.3 B 13.3 B 11.5 B 11.5 B 11.5 B 11.5 B 9.16 B 13 B 13.7 B 9.26 B 9.18 B 7.94 B 8.06 B 8.26 B 8.18 B

Total Liabilities

116 B 120 B 114 B 115 B 116 B 108 B 110 B 102 B 94.8 B 115 B 125 B 111 B 101 B - 104 B 112 B 109 B 107 B 107 B - 106 B 95.4 B 93.7 B 98.3 B 98.3 B 98.3 B 98.3 B 93.2 B 93.2 B 93.2 B 93.2 B 97.1 B 97.1 B 97.1 B 97.1 B 62.3 B 67.6 B 67.3 B 63.6 B - 61.7 B 60.9 B 60.7 B 60.6 B 61.4 B 61.4 B 61.4 B 58.6 B 58.6 B 58.6 B 58.6 B 56.5 B 56.5 B 56.5 B 56.5 B 46.3 B 50.3 B 50 B 48.3 B 41 B 39.4 B 40.5 B 41.2 B 41.2 B

Retained Earnings

172 B 169 B 167 B 165 B 163 B 155 B 155 B 153 B 153 B 129 B 125 B 128 B 128 B - 124 B 114 B 121 B 120 B 117 B - 115 B 114 B 113 B 111 B 111 B 111 B 111 B 106 B 106 B 106 B 106 B 102 B 102 B 102 B 102 B 104 B 109 B 107 B 105 B - 103 B 101 B 98.7 B 97.2 B 97.2 B 97.2 B 97.2 B 89.5 B 89.5 B 89.5 B 89.5 B 86 B 86 B 86 B 86 B 77.8 B 82.6 B 80.8 B 79.5 B 77.3 B 75.3 B 73.2 B 69.5 B 67.4 B

Total Assets

201 B 201 B 193 B 193 B 194 B 178 B 181 B 172 B 166 B 192 B 196 B 187 B 175 B - 178 B 175 B 179 B 176 B 173 B - 171 B 158 B 155 B 158 B 158 B 158 B 158 B 153 B 153 B 153 B 153 B 157 B 157 B 157 B 157 B 133 B 140 B 140 B 136 B - 133 B 132 B 129 B 130 B 131 B 131 B 131 B 133 B 133 B 133 B 133 B 121 B 121 B 121 B 121 B 103 B 112 B 112 B 108 B 98.2 B 92.3 B 93.4 B 91.6 B 87.4 B

Cash and Cash Equivalents

20.4 B 21.7 B 18.2 B 18.6 B 38.5 B 20 B 24.9 B 25.5 B 19.7 B 21.2 B 26.9 B 14.1 B 11.4 B 11 B 10.5 B 14 B 17.6 B 14.3 B 12.7 B - 19 B 11.2 B 15.5 B 17.3 B 17.3 B 17.3 B 17.3 B 18.1 B 18.1 B 18.1 B 18.1 B 17.8 B 17.8 B 17.8 B 17.8 B 13.7 B 18.2 B 18.6 B 13.9 B - 13.6 B 10.6 B 12 B 14.5 B 14.5 B 14.5 B 14.5 B 20.9 B 20.9 B 20.9 B 20.9 B 14.9 B 14.9 B 14.9 B 14.9 B 19.4 B 15.6 B 15 B 22.4 B 14.3 B 12.7 B 13.7 B 11.9 B 11.7 B

Book Value

85 B 81.2 B 79.3 B 78.5 B 78.1 B 70.2 B 71.5 B 70 B 71.2 B 76.4 B 70.9 B 76.8 B 74.6 B - 74.7 B 63.3 B 70.3 B 69.6 B 65.8 B - 64.5 B 63 B 61.3 B 59.5 B 59.5 B 59.5 B 59.5 B 59.8 B 59.8 B 59.8 B 59.8 B 60.2 B 60.2 B 60.2 B 60.2 B 71.2 B 72.8 B 72.5 B 72.6 B - 71.6 B 71.1 B 67.9 B 69.8 B 69.8 B 69.8 B 69.8 B 74.1 B 74.1 B 74.1 B 74.1 B 64.8 B 64.8 B 64.8 B 64.8 B 56.6 B 61.5 B 62.1 B 59.9 B 57.3 B 52.9 B 52.9 B 50.4 B 46.2 B

Total Shareholders Equity

85 B 81.2 B 79.3 B 78.5 B 78.1 B 70.2 B 71.5 B 70 B 71.2 B 76.4 B 70.9 B 76.8 B 74.6 B 76.4 B 74.7 B 63.3 B 70.3 B 69.6 B 65.8 B - 64.5 B 63 B 61.3 B 59.5 B 59.5 B 59.5 B 59.5 B 59.8 B 59.8 B 59.8 B 59.8 B 60.2 B 60.2 B 60.2 B 60.2 B 71.2 B 72.8 B 72.5 B 72.6 B - 71.6 B 71.1 B 67.9 B 69.8 B 69.8 B 69.8 B 69.8 B 74.1 B 74.1 B 74.1 B 74.1 B 64.8 B 64.8 B 64.8 B 64.8 B 56.6 B 61.5 B 62.1 B 59.9 B 57.3 B 52.9 B 52.9 B 50.4 B 46.2 B

All numbers in USD currency

Balance Sheet is a fundamental financial report of Johnson & Johnson, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Geron Corporation Geron Corporation
GERN
$ 1.48 3.87 % $ 987 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
INmune Bio INmune Bio
INMB
$ 1.7 4.94 % $ 42.1 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
$ 110.57 - $ 9.34 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Alkermes plc Alkermes plc
ALKS
$ 52.55 -0.64 % $ 8.66 B irlandaIrlanda
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.13 0.41 % $ 267 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA